| The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS (NCT05229861) | Klinik Valens | 2022-05-10 |
| A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (NCT05232825) | Hoffmann-La Roche | 2022-05-03 |
| Metformin Treatment in Progressive Multiple Sclerosis (NCT05349474) | University of California, Los Angeles | 2022-04-26 |
| Gray Matter Demyelination in Primary Progressive MS at 7T (NCT04977622) | Danish Research Centre for Magnetic Resonance | 2021-11-30 |
| Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS (NCT05029609) | Tiziana Life Sciences LTD | 2021-10-01 |
| Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (NCT04688788) | Rigshospitalet, Denmark | 2021-04-28 |
| Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis (NCT04943289) | Joanne Kurtzberg, MD | 2021-01-24 |
| SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (NCT03783416) | Queen Mary University of London | 2020-06-15 |
| Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 (NCT03691077) | Assistance Publique - Hôpitaux de Paris | 2018-11-11 |
| Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus (NCT03562975) | University of South Florida | 2018-07-23 |
| Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis (NCT03493841) | Rebecca Spain | 2018-06-08 |
| Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS (NCT03362294) | Mapi Pharma Ltd. | 2017-12-11 |
| Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (NCT03283826) | Atara Biotherapeutics | 2017-10-19 |
| Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis (NCT02959658) | Rigshospitalet, Denmark | 2016-12-01 |
| Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis (NCT03094364) | University of Massachusetts, Lowell | 2015-11-01 |
| Mitochondrial Dysfunction and Disease Progression (NCT02549703) | Icahn School of Medicine at Mount Sinai | 2015-09-01 |
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (NCT02284568) | Teva Branded Pharmaceutical Products R&D, Inc. | 2015-01-12 |
| A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (NCT02253264) | Johns Hopkins University | 2014-11-01 |
| Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS (NCT02273635) | Innobioscience SpA | 2014-09-01 |
| ACTH in Progressive Forms of MS (NCT01950234) | University of Minnesota | 2014-04-17 |
| A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS (NCT02208050) | University College Dublin | 2014-02-21 |
| Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study (NCT01776060) | Duke University | 2013-01-01 |
| Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition (NCT01466114) | University of California, Los Angeles | 2011-10-01 |
| Tear Analysis in the Diagnosis of Multiple Sclerosis (NCT02016222) | Lille Catholic University | 2011-04-01 |
| Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (NCT01191996) | Innate Immunotherapeutics | 2010-08-01 |
| Natalizumab Treatment of Progressive Multiple Sclerosis (NCT01077466) | Rigshospitalet, Denmark | 2010-03-01 |
| This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (NCT00731692) | Novartis Pharmaceuticals | 2008-07-28 |